Skip to content
  • Sunday, 26 July 2026
  • 1:46 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • What if psilocybin works about as well for depression as an SSRI?
Laboratory Automation & Robotics

What if psilocybin works about as well for depression as an SSRI?

Lana Keisha Jul 24, 2026 0

The burgeoning optimism surrounding classic psychedelics as a transformative treatment for depression is beginning to face a crucial reality check.…

Read More
Laboratory Automation & Robotics

Insuring the Trip: An Underwriter on What It Will Take for Approved Psilocybin to Become a Real Business

Lana Keisha Jul 23, 2026 0

More than five decades after the Controlled Substances Act, signed by President Richard Nixon in 1970, classified psilocybin as a…

Read More
Neuroscience & Brain Research

Psilocybin Induces Lasting Brain Connectivity Changes and Psychological Insight According to New UCSF and Imperial College London Study

Rifan Muazin Jul 22, 2026 0

A groundbreaking study conducted by researchers at the University of California, San Francisco (UCSF) and Imperial College London has revealed…

Read More
Laboratory Automation & Robotics

What if psilocybin works about as well for depression as an SSRI?

Lana Keisha Jul 17, 2026 0

The burgeoning optimism surrounding classic psychedelics as revolutionary treatments for depression may need a recalibration, as emerging data suggests their…

Read More
Laboratory Automation & Robotics

Insuring the trip: an underwriter on what it will take for approved psilocybin can become a real business

Lana Keisha Jul 15, 2026 0

More than five decades after the Controlled Substances Act, signed by President Richard Nixon in 1970, categorized psilocybin as a…

Read More
Laboratory Automation & Robotics

What if psilocybin works about as well for depression as an SSRI?

Lana Keisha Jul 9, 2026 0

Emerging data from recent studies and meta-analyses suggest that the highly anticipated efficacy of classic psychedelics, particularly psilocybin, in treating…

Read More
Laboratory Automation & Robotics

Insuring the Trip: An Underwriter on What It Will Take for Approved Psilocybin to Become a Real Business

Lana Keisha Jul 8, 2026 0

The landscape of mental health treatment is on the cusp of a profound transformation, with psilocybin, a compound once relegated…

Read More
Laboratory Automation & Robotics

What if psilocybin works about as well for depression as an SSRI?

Lana Keisha Jul 2, 2026 0

The burgeoning hope surrounding classic psychedelics as a transformative treatment for depression is beginning to confront the sobering realities of…

Read More
Laboratory Automation & Robotics

Insuring the trip: an underwriter on what it will take for approved psilocybin can become a real business

Lana Keisha Jun 30, 2026 0

More than five decades after the Controlled Substances Act, signed by President Richard Nixon in 1970, categorized psilocybin as a…

Read More
Laboratory Automation & Robotics

What if psilocybin works about as well for depression as an SSRI?

Lana Keisha Jun 25, 2026 0

The fervent hope surrounding classic psychedelics as a revolutionary treatment for depression may be tempering, with recent data suggesting that…

Read More

Posts pagination

1 2
Medvi: The $1.8 Billion Telehealth Company Built on Regulatory Gaps, Fake Testimonials, and AI DeceptionInvasive goldfish trigger a regime shift in experimental lake ecosystems of varying trophic stateBreakthrough in Blue Energy: Lipid-Coated Nanopores Triple Power Density of Osmotic Power SystemsBacteria Navigate Surfaces Through Unexpected Metabolic and Molecular Mechanisms
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ